For the year ending 2025-12-31, LSTA had -$253K decrease in cash & cash equivalents over the period. -$15,977K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -16,586 |
| Share-based compensation expense | 1,226 |
| Depreciation and amortization | 146 |
| Loss from equity method investment | 0 |
| Impairment of non-financial asset | 127 |
| Amortization/accretion on marketable securities | 75 |
| Allowance for credit losses | 500 |
| Accounts receivable | -401 |
| Prepaid and other current assets | -742 |
| Other assets | -140 |
| Accounts payable, accrued liabilities and other liabilities | -2,570 |
| Net cash used in operating activities | -15,949 |
| Purchase of marketable securities | 9,180 |
| Sales of marketable securities | 24,294 |
| Investment in impilo therapeutics | 0 |
| Purchases of property and equipment | 28 |
| Net cash provided by investing activities | 15,086 |
| Proceeds from exercise of options | 8 |
| Tax withholding payments on net share settlement equity awards | 253 |
| Net proceeds from issuance of common stock | 844 |
| Net cash provided by (used in) financing activities | 599 |
| Effect of exchange rate changes on cash | 11 |
| Net decrease in cash and cash equivalents | -253 |
| Cash and cash equivalents at beginning of year | 16,209 |
| Cash and cash equivalents at end of year | 15,956 |
LISATA THERAPEUTICS, INC. (LSTA)
LISATA THERAPEUTICS, INC. (LSTA)